Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-0.64% $20.29
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 877.04 mill |
EPS: | -2.32 |
P/E: | -8.75 |
Earnings Date: | Apr 29, 2024 |
SharesOutstanding: | 43.23 mill |
Avg Daily Volume: | 0.686 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.75 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.49x |
Company: PE -8.75 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.89 (-85.76%) $-17.40 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 19.11 - 21.47 ( +/- 5.80%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-06 | Nicaise Claude | Buy | 20 000 | Stock Option (Right to Buy) |
2023-12-06 | Nicaise Claude | Buy | 0 | |
2023-12-06 | Gravier Pierre | Buy | 20 000 | Stock Option (Right to Buy) |
2023-12-06 | Anderson Robert Eugene Jr | Buy | 20 000 | Stock Option (Right to Buy) |
2023-12-06 | Gravier Pierre | Buy | 0 |
INSIDER POWER |
---|
78.87 |
Last 90 transactions |
Buy: 1 816 102 | Sell: 547 962 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $20.29 (-0.64% ) |
Volume | 0.468 mill |
Avg. Vol. | 0.686 mill |
% of Avg. Vol | 68.25 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.39 | N/A | Active |
---|
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.